Login

Novo-Nordisk A/S

NVO Pharmaceuticals Market cap — Share price × shares outstanding (not in data file).
$39.13 ▲ +0.20%
+$0.08 on the day · as of 27 Oct 2026
57
S.I.F.T.™ score
Caution
Rules-based score out of 100 across Safety, Income, Fundamentals and Time. Strong 80+, Adequate 60–79, Caution under 60. A band describes the score, not an action.
Login to Issue Journal Login to Add Portfolio

S.I.F.T.™ pillars One or more pillars are weak.

Safety58
Decent financial position but faces notable competition.
Income70
High cyclicality and lack of recurring revenue are limiting stability.
Fundamentals55
Strong growth but valuation is elevated.
Time45
Shorter track record or weaker tailwinds.
Last updated: 27 Oct 2026 · Model score (rules-based screen of the data shown; not advice or a forecast): 70%
Reality check (rules-based) S.I.F.T. band: Caution

Strong (80+) · Adequate (60–79) · Caution (<60). A band describes the score, not an action.

The company shows a 10-year average ROE of 59.1% with a net debt to CFO ratio of 3.6 and dividend yield of 1.0%. Income stability pillar scores highest at 70 while time in market scores lowest at 45.

Strengths: Income stability pillar at 70, ROE 10yr avg 59.1%, Safety pillar at 58
Risks: Time in market pillar at 45, Fundamentals pillar at 55, Cash to market cap at 0

For education and general information only. Not a recommendation to buy, sell, or hold. How the score is calculated

Price History

At its core

The fundamentals file for this company has not been loaded yet. It is fetched in the background; check back shortly.

For education and general information only. Not a recommendation to buy, sell, or hold. How the score is calculated

The business

With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

FAQ

Financial details

The annual and quarterly figures for this company have not been loaded yet. They are fetched in the background; check back shortly.